融合生検の世界市場2020-2027:生検ルート別(経直腸、経会陰)、エンドユース別(病院、診断センター、外来医療センター)、地域別

◆英語タイトル:Fusion Biopsy Market Size, Share & Trends Analysis Report By Biopsy Route (Transrectal, Transperineal), By End-use (Hospitals, Diagnostic Centers, Ambulatory Care Centers), By Region, And Segment Forecasts, 2020 - 2027
◆商品コード:GV20SP0045
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2020年8月10日
◆ページ数:130
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥654,500見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥764,500見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥984,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Grand View Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは融合生検の世界市場について詳細に調査・分析し、調査手法・範囲、エグゼクティブサマリー、市場要因・動向・範囲、生検ルート別(経直腸、経会陰)分析、エンドユース別(病院、診断センター、外来医療センター)分析、地域別分析、競争状況などを掲載しています。
・調査手法・範囲
・エグゼクティブサマリー
・市場要因・動向・範囲
・融合生検の世界市場規模:生検ルート別(経直腸、経会陰)
・融合生検の世界市場規模:エンドユース別(病院、診断センター、外来医療センター)
・融合生検の世界市場規模:地域別
・競争状況
【レポートの概要】

Fusion Biopsy Market Growth & Trends

The global fusion biopsy market size is estimated to reach USD 1.1 billion by 2027 registering a CAGR of 10.3%, according to a new report by Grand View Research, Inc. The increasing prevalence of prostate cancer, growing demand for targeted biopsy, and the rising utilization rate of multiparametric MRI in prostate cancer care are factors expected to drive the market during the forecast period.

High sensitivity and specificity of targeted MR/Ultrasound fusion biopsy in delineating prostate lesions compared to other traditional technologies such as TRUS biopsy, PSA test, or Digital Rectal Examination is expected to contribute to the market growth. The reliability and reproducibility of the fusion biopsy system in diagnosis of aggressive tumors is expected to make it as a standard tool in prostate biopsy.

An increasing number of radiologists gaining expertise in interpreting prostate MRI coupled with the implementation of standard image grading systems such as PI-RADS and Gleason score has increased the utilization rate of targeted MR/Ultrasound fusion biopsy system.

The increasing number of government initiatives in terms of funding research, spreading awareness, and conducting mass screening programs related to prostate cancer are expected to play a crucial in the growth of the market. Some of the growth strategies adopted by market players include partnership, product launch, participation in trade events and conferences, and acquisitions to sustain in this highly competitive market.

Fusion Biopsy Market Report Highlights

• The transrectal segment held the largest market share in 2019, as it is the gold standard and commonly used method of prostate fusion biopsy

• The transperineal segment is expected to grow at the fastest rate during the forecast period owing to the safety, diagnostic efficiency, and ability to access the ventral prostate areas

• The hospital segment accounted for the largest revenue share in 2019 because of the factors such as increasing the procurement rate of MR/US targeted fusion biopsy system in teaching hospitals

• The diagnostics centers segment is expected to grow at a significant rate over the forecast period. Shorter wait times, cost efficiency, and developing reimbursement paradigm are the factors expected to drive the growth of this segment

• North America held the largest market share in the market in 2019 and is anticipated to maintain its dominance over the forecast period

• Asia Pacific is anticipated to witness a CAGR of 10.5% during the forecast period owing to factors such as growing awareness about the sensitivity and specificity of MRI/US targeted fusion biopsy systems among urologists especially in countries such as Japan, Australia, and China.

【レポートの目次】

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Biopsy route
1.1.2. End-use
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.3.5.1. Data for primary interviews in North America
1.3.5.2. Data for primary interviews in Europe
1.3.5.3. Data for primary interviews in Asia Pacific
1.3.5.4. Data for primary interviews in Latin America
1.3.5.5. Data for Primary interviews in MEA
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Biopsy route outlook
2.2.2. End-use outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Fusion Biopsy Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Industry Value Chain Analysis
3.3.1. Reimbursement framework
3.4. Market Dynamics
3.4.1. Market driver analysis
3.4.1.1. Increasing prevalence of prostate cancer
3.4.1.2. Technological advancements in fusion imaging modalities
3.4.1.3. Increasing funds and investments by public and private sector
3.4.2. Market restraint analysis
3.4.2.1. High cost of fusion biopsy system
3.4.2.2. Liquid biopsy system
3.5. Fusion Biopsy Market Analysis Tools
3.5.1. Industry analysis – Porter’s
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL analysis
3.5.2.1. Political landscape
3.5.2.2. Technological landscape
3.5.2.3. Economic landscape
3.5.3. Major deals & strategic alliances analysis
3.5.4. Market entry strategies
Chapter 4. Fusion Biopsy Market: Biopsy Route Estimates & Trend Analysis
4.1. Definitions and Scope
4.1.1. Transrectal
4.1.2. Transperineal
4.2. Biopsy Route Market Share, 2019 & 2027
4.3. Segment Dashboard
4.4. Global Fusion Biopsy Market by Biopsy Route Outlook
4.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
4.5.1. Transrectal
4.5.1.1. Market estimates and forecast, 2016 – 2027 (Revenue, USD Million)
4.5.2. Transperineal
4.5.2.1. Market estimates and forecast, 2016 – 2027 (Revenue, USD Million)
Chapter 5. Fusion Biopsy Market: End-use Estimates & Trend Analysis
5.1. Definitions and Scope
5.1.1. Hospitals
5.1.2. Diagnosticcenters
5.1.3. Ambulatory care centers
5.2. End-use, 2019 & 2027
5.3. Segment Dashboard
5.4. Fusion Biopsy Market by End use Outlook
5.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
5.5.1. Hospitals
5.5.1.1. Market estimates and forecast, 2016 – 2027 (Revenue, USD Million)
5.5.2. Diagnostic centers
5.5.2.1. Market estimates and forecast, 2016 – 2027 (Revenue, USD Million)
5.5.3. Ambulatory Care Centers
5.5.3.1. Market estimates and forecast, 2016 – 2027 (Revenue, USD Million)
Chapter 6. Fusion Biopsy Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2019 & 2027
6.2. Regional Market Dashboard
6.3. Regional Market Snapshot
6.4. Regional Market Share and Leading Players, 2019
6.4.1. North America
6.4.2. Europe
6.4.3. Asia Pacific
6.4.4. Latin America
6.4.5. Middle East and Africa
6.5. SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
6.5.1. North America
6.5.2. Europe
6.5.3. Asia Pacific
6.5.4. Latin America
6.5.5. Middle East and Africa
6.6. Market Size, & Forecasts, Volume and Trend Analysis, 2019 to 2027:
6.7. North America
6.7.1. The U.S.
6.7.1.1. Market estimates and forecast, 2016 – 2027 (Revenue, USD Million)
6.7.2. Canada
6.7.2.1. Market estimates and forecast, 2016 – 2027 (Revenue, USD Million)
6.8. Europe
6.8.1. The U.K.
6.8.1.1. Market estimates and forecast, 2016 – 2027 (Revenue, USD Million)
6.8.2. Germany
6.8.2.1. Market estimates and forecast, 2016 – 2027 (Revenue, USD Million)
6.8.3. France
6.8.3.1. Market estimates and forecast, 2016 – 2027 (Revenue, USD Million)
6.8.4. Italy
6.8.4.1. Market estimates and forecast, 2016 – 2027 (Revenue, USD Million)
6.8.5. Spain
6.8.5.1. Market estimates and forecast, 2016 – 2027 (Revenue, USD Million)
6.8.6. Switzerland
6.8.6.1. Market estimates and forecast, 2016 – 2027 (Revenue, USD Million)
6.8.7. Belgium
6.8.7.1. Market estimates and forecast, 2016 – 2027 (Revenue, USD Million)
6.9. Asia Pacific
6.9.1. Japan
6.9.1.1. Market estimates and forecast, 2016 – 2027 (Revenue, USD Million)
6.9.2. China
6.9.2.1. Market estimates and forecast, 2016 – 2027 (Revenue, USD Million)
6.9.3. India
6.9.3.1. Market estimates and forecast, 2016 – 2027 (Revenue, USD Million)
6.9.4. South Korea
6.9.4.1. Market estimates and forecast, 2016 – 2027 (Revenue, USD Million)
6.9.5. Thailand
6.9.5.1. Market estimates and forecast, 2016 – 2027 (Revenue, USD Million)
6.9.6. Australia
6.9.6.1. Market estimates and forecast, 2016 – 2027 (Revenue, USD Million)
6.10. Latin America
6.10.1. Brazil
6.10.1.1. Market estimates and forecast, 2016 – 2027 (Revenue, USD Million)
6.10.2. Mexico
6.10.2.1. Market estimates and forecast, 2016 – 2027 (Revenue, USD Million)
6.10.3. Argentina
6.10.3.1. Market estimates and forecast, 2016 – 2027 (Revenue, USD Million)
6.11. MEA
6.11.1. South Africa
6.11.1.1. Market estimates and forecast, 2016 – 2027 (Revenue, USD Million)
6.11.2. Saudi Arabia
6.11.2.1. Market estimates and forecast, 2016 – 2027 (Revenue, USD Million)
6.11.3. UAE
6.11.3.1. Market estimates and forecast, 2016 – 2027 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competitive Categorization
7.2.1. Innovators
7.2.2. Market leaders
7.2.3. Emerging players
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company market share analysis, 2019
7.4. Public Companies
7.4.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
7.4.2. Company market share/ranking, by region
7.4.3. Competitive dashboard analysis
7.4.3.1. Market differentiators
7.4.3.2. Synergy analysis: major deals and strategic alliances
7.5. Private Companies
7.5.1. List of key emerging companies/technology disruptors/innovators
7.5.2. Funding outlook
7.5.3. Regional network map
7.5.4. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)
7.5.5. Supplier ranking
7.5.6. Key company profiled
7.5.7. Eigen
7.5.7.1. Company overview
7.5.7.2. Financial performance
7.5.7.3. Product benchmarking
7.5.7.4. Strategic initiatives
7.5.8. Koninklijke Philips N.V.
7.5.8.1. Company overview
7.5.8.2. Financial performance
7.5.8.3. Product benchmarking
7.5.8.4. Strategic initiatives
7.5.9. Hitachi, Ltd.
7.5.9.1. Company overview
7.5.9.2. Financial performance
7.5.9.3. Product benchmarking
7.5.9.4. Strategic initiatives
7.5.10. MedCom
7.5.10.1. Company overview
7.5.10.2. Financial performance
7.5.10.3. Product benchmarking
7.5.10.4. Strategic initiatives
7.5.11. ESAOTE SPA
7.5.11.1. Company overview
7.5.11.2. Financial performance
7.5.11.3. Product benchmarking
7.5.11.4. Strategic initiatives
7.5.12. KOELIS
7.5.12.1. Company overview
7.5.12.2. Financial performance
7.5.12.3. Product benchmarking
7.5.12.4. Strategic initiatives
7.5.13. Focal Healthcare
7.5.13.1. Company overview
7.5.13.2. Financial performance
7.5.13.3. Product benchmarking
7.5.13.4. Strategic initiatives
7.5.14. GeoScan Medical
7.5.14.1. Company overview
7.5.14.2. Financial performance
7.5.14.3. Product benchmarking
7.5.14.4. Strategic initiatives
7.5.15. UC-Care Medical Systems Ltd.
7.5.15.1. Company overview
7.5.15.2. Financial performance
7.5.15.3. Product benchmarking
7.5.15.4. Strategic initiatives

List of Tables

Table 1 List of Abbreviation
Table 2 North America fusion biopsy market, by region, 2016 - 2027 (USD Million)
Table 3 North America fusion biopsy market, by biopsy route, 2016 - 2027 (USD Million)
Table 4 North America fusion biopsy market, by end-use, 2016 - 2027 (USD Million)
Table 5 The U.S. fusion biopsy market, by biopsy route, 2016 - 2027 (USD Million)
Table 6 The U.S. fusion biopsy market, by end-use, 2016 - 2027 (USD Million)
Table 7 Canada fusion biopsy market, by biopsy route, 2016 - 2027 (USD Million)
Table 8 Canada fusion biopsy market, by end-use, 2016 - 2027 (USD Million)
Table 9 Europe fusion biopsy market, by region, 2016 - 2027 (USD Million)
Table 10 Europe fusion biopsy market, by biopsy route, 2016 - 2027 (USD Million)
Table 11 Europe fusion biopsy market, by end-use, 2016 - 2027 (USD Million)
Table 12 The U.K. fusion biopsy market, by biopsy route, 2016 - 2027 (USD Million)
Table 13 The U.K. fusion biopsy market, by end-use, 2016 - 2027 (USD Million)
Table 14 Germany fusion biopsy market, by biopsy route, 2016 - 2027 (USD Million)
Table 15 Germany fusion biopsy market, by end-use, 2016 - 2027 (USD Million)
Table 16 Italy fusion biopsy market, by biopsy route, 2016 - 2027 (USD Million)
Table 17 Italy fusion biopsy market, by end-use, 2016 - 2027 (USD Million)
Table 18 France fusion biopsy market, by biopsy route, 2016 - 2027 (USD Million)
Table 19 France fusion biopsy market, by end-use, 2016 - 2027 (USD Million)
Table 20 Spain fusion biopsy market, by biopsy route, 2016 - 2027 (USD Million)
Table 21 Spain fusion biopsy market, by end-use, 2016 - 2027 (USD Million)
Table 22 Switzerland fusion biopsy market, by biopsy route, 2016 - 2027 (USD Million)
Table 23 Switzerland fusion biopsy market, by end-use, 2016 - 2027 (USD Million)
Table 24 Belgium fusion biopsy market, by biopsy route, 2016 - 2027 (USD Million)
Table 25 Belgium fusion biopsy market, by end-use, 2016 - 2027 (USD Million)
Table 26 Asia Pacific fusion biopsy market, by region, 2016 - 2027 (USD Million)
Table 27 Asia Pacific fusion biopsy market, by biopsy route, 2016 - 2027 (USD Million)
Table 28 Asia Pacific fusion biopsy market, by end-use, 2016 - 2027 (USD Million)
Table 29 Japan fusion biopsy market, by biopsy route, 2016 - 2027 (USD Million)
Table 30 Japan fusion biopsy market, by end-use, 2016 - 2027 (USD Million)
Table 31 India fusion biopsy market, by biopsy route, 2016 - 2027 (USD Million)
Table 32 India fusion biopsy market, by end-use, 2016 - 2027 (USD Million)
Table 33 China fusion biopsy market, by biopsy route, 2016 - 2027 (USD Million)
Table 34 China fusion biopsy market, by end-use, 2016 - 2027 (USD Million)
Table 35 Thailand fusion biopsy market, by biopsy route, 2016 - 2027 (USD Million)
Table 36 Thailand fusion biopsy market, by end-use, 2016 - 2027 (USD Million)
Table 37 South Korea fusion biopsy market, by biopsy route, 2016 - 2027 (USD Million)
Table 38 South Korea fusion biopsy market, by end-use, 2016 - 2027 (USD Million)
Table 39 Australia fusion biopsy market, by biopsy route, 2016 - 2027 (USD Million)
Table 40 Australia fusion biopsy market, by end-use, 2016 - 2027 (USD Million)
Table 41 Latin America fusion biopsy market, by region, 2016 - 2027 (USD Million)
Table 42 Latin America fusion biopsy market, by biopsy route, 2016 - 2027 (USD Million)
Table 43 Latin America fusion biopsy market, by end-use, 2016 - 2027 (USD Million)
Table 44 Brazil fusion biopsy market, by biopsy route, 2016 - 2027 (USD Million)
Table 45 Brazil fusion biopsy market, by end-use, 2016 - 2027 (USD Million)
Table 46 Mexico fusion biopsy market, by biopsy route, 2016 - 2027 (USD Million)
Table 47 Mexico fusion biopsy market, by end-use, 2016 - 2027 (USD Million)
Table 48 Argentina fusion biopsy market, by biopsy route, 2016 - 2027 (USD Million)
Table 49 Argentina fusion biopsy market, by end-use, 2016 - 2027 (USD Million)
Table 50 MEA fusion biopsy market, by region, 2016 - 2027 (USD Million)
Table 51 MEA fusion biopsy market, by biopsy route, 2016 - 2027 (USD Million)
Table 52 MEA fusion biopsy market, by end-use, 2016 - 2027 (USD Million)
Table 53 South Africa fusion biopsy market, by biopsy route, 2016 - 2027 (USD Million)
Table 54 South Africa fusion biopsy market, by end-use, 2016 - 2027 (USD Million)
Table 55 Saudi Arabia fusion biopsy market, by biopsy route, 2016 - 2027 (USD Million)
Table 56 Saudi Arabia fusion biopsy market, by end-use, 2016 - 2027 (USD Million)
Table 57 UAE fusion biopsy market, by biopsy route, 2016 - 2027 (USD Million)
Table 58 UAE fusion biopsy market, by end-use, 2016 - 2027 (USD Million)


List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Fusion biopsy market: market outlook
Fig. 14 Fusion biopsy market competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Penetration and growth prospect mapping
Fig. 18 Industry value chain analysis
Fig. 19 Fusion biopsy market driver impact
Fig. 20 Fusion biopsy market restraint impact
Fig. 21 Fusion biopsy market strategic initiatives analysis
Fig. 22 Fusion biopsy market: biopsy route movement analysis
Fig. 23 Fusion biopsy market: biopsy route outlook and key takeaways
Fig. 24 Transrectal market estimates and forecast, 2016 - 2027
Fig. 25 Transperineal market estimates and forecast, 2016 - 2027
Fig. 26 Fusion biopsy market: end-use movement analysis
Fig. 27 Fusion biopsy market: end-use outlook and key takeaways
Fig. 28 Hospitals market estimates and forecast, 2016 - 2027
Fig. 29 Diagnostic centers market estimates and forecast, 2016 - 2027
Fig. 30 Ambulatory care centers market estimates and forecast, 2016 - 2027
Fig. 31 Fusion biopsy market: regional movement analysis
Fig. 32 Fusion biopsy market: regional outlook and key takeaways
Fig. 33 Fusion biopsy market share and leading players
Fig. 34 North America market share and leading players
Fig. 35 Europe market share and leading players
Fig. 36 Asia Pacific market share and leading players
Fig. 37 Latin America market share and leading players
Fig. 38 Middle East & Africa market share and leading players
Fig. 39 North America: SWOT
Fig. 40 Europe SWOT
Fig. 41 Asia Pacific SWOT
Fig. 42 Latin America SWOT
Fig. 43 MEA SWOT
Fig. 44 North America, by country
Fig. 45 North America
Fig. 46 North America market estimates and forecast, 2016 - 2027
Fig. 47 The U.S.
Fig. 48 The U.S. market estimates and forecast, 2016 - 2027
Fig. 49 Canada
Fig. 50 Canada market estimates and forecast, 2016 - 2027
Fig. 51 Europe
Fig. 52 Europe market estimates and forecast, 2016 - 2027
Fig. 53 The U.K.
Fig. 54 The U.K. market estimates and forecast, 2016 - 2027
Fig. 55 Germany
Fig. 56 Germany market estimates and forecast, 2016 - 2027
Fig. 57 France
Fig. 58 France market estimates and forecast, 2016 - 2027
Fig. 59 Italy
Fig. 60 Italy market estimates and forecast, 2016 - 2027
Fig. 61 Spain
Fig. 62 Spain market estimates and forecast, 2016 - 2027
Fig. 63 Switzerland
Fig. 64 Switzerland market estimates and forecast, 2016 - 2027
Fig. 65 Belgium
Fig. 66 Belgium market estimates and forecast, 2016 - 2027
Fig. 67 Asia Pacific
Fig. 68 Asia Pacific market estimates and forecast, 2016 - 2027
Fig. 69 China
Fig. 70 China market estimates and forecast, 2016 - 2027
Fig. 71 Japan
Fig. 72 Japan market estimates and forecast, 2016 - 2027
Fig. 73 India
Fig. 74 India market estimates and forecast, 2016 - 2027
Fig. 75 Thailand
Fig. 76 Thailand market estimates and forecast, 2016 - 2027
Fig. 77 South Korea
Fig. 78 South Korea market estimates and forecast, 2016 - 2027
Fig. 79 Australia
Fig. 80 Australia market estimates and forecast, 2016 - 2027
Fig. 81 Latin America
Fig. 82 Latin America market estimates and forecast, 2016 - 2027
Fig. 83 Brazil
Fig. 84 Brazil market estimates and forecast, 2016 - 2027
Fig. 85 Mexico
Fig. 86 Mexico market estimates and forecast, 2016 - 2027
Fig. 87 Argentina
Fig. 88 Argentina market estimates and forecast, 2016 - 2027
Fig. 89 Middle East and Africa
Fig. 90 Middle East and Africa. market estimates and forecast, 2016 - 2027
Fig. 91 South Africa
Fig. 92 South Africa market estimates and forecast, 2016 - 2027
Fig. 93 Saudi Arabia
Fig. 94 Saudi Arabia market estimates and forecast, 2016 - 2027
Fig. 95 UAE
Fig. 96 UAE market estimates and forecast, 2016 - 2027
Fig. 97 Participant categorization- fusion biopsy market
Fig. 98 Market share of key market players- fusion biopsy market

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[融合生検の世界市場2020-2027:生検ルート別(経直腸、経会陰)、エンドユース別(病院、診断センター、外来医療センター)、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆